Journal: The Journal of Biological Chemistry

Article Title: Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3

doi: 10.1016/j.jbc.2026.111417

Figure Lengend Snippet: Fortilin physically binds MEF2C. A, quantitative RT–PCR (qRT–PCR) analysis of THP1 WT-fortilin and THP1 KO-fortilin cells ( n = 3, p < 0.0001, two-sample t test). B – E, MST to characterize the interaction of fortilin with MEF2 family proteins, MEF2A, MEF2B, MEF2C, and MEF2D. K d s were calculated using NanoTemper Analysis software based on the relative F norm values. F – I, in vivo forward co-IP assays. Fortilin was immunoprecipitated from the TCLs of 293T cells using an α-fortilin Ab. Successful IP of fortilin and co-IP of MEF2C and other MEF2 isoforms were assessed by Western blotting using α-fortilin Ab and Abs against MEF2A, MEF2B, MEF2C, and MEF2D, respectively. Total protein was visualized in the SDS-gel containing TCE. J, in vivo reverse co-IP assay. MEF2C was immunoprecipitated from the 293T TCL using an α-MEF2C Ab. Successful IP of MEF2C and co-IP of fortilin were assessed by Western blotting using α-MEF2C and α-fortilin Abs, respectively. Total protein was visualized in an SDS-gel containing TCE. K and L, PLA to evaluate the fortilin–MEF2C interaction. Phorbol 12-myristate 13-acetate-treated THP1 WT-fortilin and THP1 KO-fortilin cells cultured on chamber slides were subjected to a standard PLA assay using rabbit α-fortilin and mouse α-MEF2C Abs. Nuclei were counterstained by DAPI ( blue ). Red puncta indicated that fortilin and MEF2C were located within 30 nm of each other. The scale bar represents 50 μm. K, the PLA interaction index was calculated as the number of PLA puncta per nucleus within a field of view and expressed in AU. Three fields were quantified for each sample, and three independent experiments were performed. Statistical significance was evaluated using a Welch’s two-sample t test ( L ). Ab, antibody; AU, arbitrary unit; DAPI, 4′,6-diamidino-2-phenylindole; α-FLAG, anti-FLAG (DYKDDDDK) antibody (Ab); F norlm , normalized fluorescence value; α-fortilin, rabbit anti-fortilin monoclonal Ab; Fortilin KO, THP1 cells in which the fortilin ( TPT1 ) genes have been deleted by the CRISPR–Cas9 technology (THP1 KO-fortilin ); Fortilin WT, THP1 cells expressing WT fortilin (THP1 WT-fortilin ); α-His 6 , anti-hexahistidine Ab; IB, immunoblot; IgG, normal rabbit immunoglobulin G; INPUT, 10% of TCLs used for IP; IP, immunoprecipitation; α-MEF2C, anti-MEF2C Ab; MST, microscale thermophoresis; PLA, proximity ligation assay; TCE, 2,2,2-trichloroethanol; TCL, total cell lysate.

Article Snippet: We obtained the recombinant human proteins, MEF2A (catalog no.: TP312830; cMYC-FLAG-tagged), MEF2B (catalog no.: TP327214; cMYC-FLAG-tagged), MEF2C (catalog no.: TP320584; cMYC-FLAG-tagged), MEF2D (catalog no.: TP308748; cMYC-FLAG-tagged), and fortilin (catalog no.: TP301664; cMYC-FLAG-tagged) from OriGene and His 6 - NQO2 (catalog no.: ab93933) from Abcam.

Techniques: Quantitative RT-PCR, Software, In Vivo, Co-Immunoprecipitation Assay, Immunoprecipitation, Western Blot, SDS-Gel, Cell Culture, Fluorescence, CRISPR, Expressing, Microscale Thermophoresis, Proximity Ligation Assay

Journal: The Journal of Biological Chemistry

Article Title: Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3

doi: 10.1016/j.jbc.2026.111417

Figure Lengend Snippet: Fortilin binds the N-terminal domain of MEF2C. A, MEF2C deletion mutants. Plasmids encoding MEF2C WT and two deletion mutants, MEF2C M1 and MEF2C M2 , lacking residues 1 to 85 and 1 to 270 of MEF2C, respectively, were generated on the pEZ mammalian expression vector. B, in vivo co-IP analysis of MEF2C deletion mutants. TCLs from 293T cells transfected with pEZ-MEF2C WT -FLAG, pEZ-MEF2C M1 -FLAG, or pEZ-MEF2C M2 -FLAG plasmid were subjected to IP in which FLAG-tagged MEF2C proteins were pulled down by α-FLAG Ab and the presence of coimmunoprecipitated fortilin was assessed by Western blotting using α-fortilin Ab. C, sequence alignment of the N-terminal regions of MEF2A, MEF2B, MEF2C, and MEF2D encompassing the MADS-box (residues 3–57) and MEF2 (residues 58–86) domains. Consensus amino acid residues among all four proteins are shown in bold black . Amino acids identical to those in MEF2C are highlighted in yellow . Threonine at position 51, which is uniquely present in MEF2C but absent in MEF2A, MEF2B, and MEF2D, is indicated in bold type . D, HADDOCK scores for fortilin binding to MEF2A, MEF2B, MEF2C, and MEF2D ( n = 4 per the best cluster, one-way ANOVA with Tukey’s multiple comparisons). E, representative docking model showing full-length fortilin ( blue ) in complex with the N-terminal region of MEF2C (red ). Ribbon rendering of the complex is shown with transparent surface representations for both proteins. Amino acid residues critically contributing to the binding interface are indicated for fortilin (Asp 25 , Lys 112 , Glu 120 , and Gln 121 ) in blue and MEF2C (GLN 18 , THR 51 , LYS 53 , LEU 54 , and PHE 55 ) in red . F and G, molecular dynamics simulations of the fortilin–MEF2C complex showing the RMSD time trace ( F ) and RMSD probability distribution ( G ). H, co-IP analysis of the fortilin D25A mutant. THP1 KO-fortilin cells were transiently transfected with pCS mammalian expression vectors encoding HA-tagged WT fortilin (fortilin WT ) or the mutant (fortilin D25A ). TCLs were immunoprecipitated using an anti-HA antibody, and coimmunoprecipitated MEF2C was detected by Western blotting. AU, arbitrary unit; FLAG, an epitope-tag consisting of DYKDDDDK; fortilin WT -HA, pCS-fortilin WT -3×HA plasmid that expresses the WT MEF2C fused to the three hemagglutinin (HA) epitope tag repeats at its C-terminal end; fortilin D25A -HA, pCS-fortilin D25A -3×HA; IP, immunoprecipitation; M1, pEZ-MEF2C M1 -FLAG (amino acids 86–463); M2, pEZ-MEF2C M1 -FLAG (amino acids 271–463); MADS-box, MCM1-Agamous-Deficiens-Serum Response Factor box; MEF2, myocyte enhancer factor-2; MEF2C WT , WT MEF2C (1–463 amino acids); MEF2C M1 , a deletion mutant of MEF2C lacking the N-terminal MADS-box and MEF2 domains and containing amino acids 86 to 463 of WT MEF2C; MEF2C M2 , a deletion mutant containing amino acids 271 to 463 of WT MEF2C; α-MEF2C, anti-MEF2C antibody; α-HA, anti-HA-tag antibody; TCL, total cell lysate; THP1 WT-fortilin , THP1 cells expressing WT fortilin; THP1 KO-fortilin , THP1 cells in which the fortilin genes have been deleted by the CRISPR–Cas9 technology; WT, pEZ-MEF2C WT -FLAG plasmid that expresses the WT MEF2C (amino acids 1–463) fused to the FLAG epitope tag at its C-terminal region.

Article Snippet: We obtained the recombinant human proteins, MEF2A (catalog no.: TP312830; cMYC-FLAG-tagged), MEF2B (catalog no.: TP327214; cMYC-FLAG-tagged), MEF2C (catalog no.: TP320584; cMYC-FLAG-tagged), MEF2D (catalog no.: TP308748; cMYC-FLAG-tagged), and fortilin (catalog no.: TP301664; cMYC-FLAG-tagged) from OriGene and His 6 - NQO2 (catalog no.: ab93933) from Abcam.

Techniques: Generated, Expressing, Plasmid Preparation, In Vivo, Co-Immunoprecipitation Assay, Transfection, Western Blot, Sequencing, Binding Assay, Mutagenesis, Immunoprecipitation, CRISPR, FLAG-tag

Journal: The Journal of Biological Chemistry

Article Title: Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3

doi: 10.1016/j.jbc.2026.111417

Figure Lengend Snippet: Fortilin–MEF2C interaction mitigates the ubiquitination and proteasomal degradation of MEF2C. A – D, time-course analysis of MEF2C degradation in the presence or the absence of carfilzomib using the JESS capillary-based Western blot system. THP-1 cells were transiently transfected with pEZ-MEF2C WT -FLAG, incubated for 48 h, treated with CHX in the presence or the absence of carfilzomib (defined as time 0), and harvested at the indicated time points. TCLs were analyzed by IB with α-FLAG and α-fortilin Abs to assess MEF2C WT -FLAG and fortilin expression, respectively. Total protein loading was visualized using the JESS total protein detection module ( A ). Quantitative analysis of MEF2C expression and degradation in THP1 WT-fortilin and THP1 KO-fortilin cells treated with and without carfilzomib. Four experimental groups were analyzed—THP1 WT-fortilin ± carfilzomib and THP1 KO-fortilin ± carfilzomib. MEF2C expression indices (AU) were calculated at each time point using JESS Compass software by dividing the area under the MEF2C peak by the total protein signal within the same capillary (“in-capillary normalization”). Absolute MEF2C expression levels at time 0 were first compared between THP1 WT-fortilin and THP1 KO-fortilin cells in the absence ( B ) and presence ( D ) of carfilzomib. Data are presented as means ± standard deviation with p values indicated ( n = 3, two-sample t test). MEF2C degradation kinetics were then assessed by normalizing MEF2C expression indices at each time point to the corresponding time 0 value within each group and comparing degradation profiles between THP1 WT-fortilin and THP1 KO-fortilin cells in the absence and presence of carfilzomib ( n = 3, two-sample t test) ( C ). E and F, MEF2C ubiquitination assay. MEF2C was immunoprecipitated from the TCLs of THP1 WT-fortilin and THP1 KO-fortilin cells using an anti-MEF2C Ab, and ubiquitinated MEF2C was detected by IB with an anti-ubiquitin Ab ( E ). MEF2C ubiquitination indices were calculated by normalizing the total signal intensity of ubiquitinated MEF2C to the signal intensity of unmodified MEF2C in the TCLs ( n = 3, two-sample t test) ( F ). G and H, effect of fortilin binding to MEF2C on MEF2C degradation. THP1 KO-fortilin cells were transfected with plasmids encoding fortilin WT -HA or fortilin D25A -HA (an MEF2C-binding–deficient mutant), treated with CHX, and incubated for 12 h in the presence or the absence of carfilzomib. TCLs were analyzed by Western blotting using anti-MEF2C and anti-HA Abs ( G ). MEF2C expression indices were calculated by normalizing the area under the curve of the MEF2C peak to total protein using Compass software (ProteinSimple, n = 3, ANOVA with Tukey’s multiple comparisons) ( H ). AU, arbitrary unit; carfilzomib, proteasome inhibitor; CHX, cycloheximide; α-FLAG, anti-FLAG antibody (Ab); α-fortilin, anti-fortilin Ab; fortilin D25A -HA, a HA-tagged MEF2C-binding–deficient fortilin mutant in which the 25th aspartic acid ( D ) is mutated to alanine ( A ); fortilin WT -HA, HA-tagged WT fortilin; IB, immunoblot; α-MEF2C, anti-MEF2C Ab; MG132, carbobenzoxy-L-leucyl-L-leucyl-L-leucine (proteasome inhibitor); TCL, total cell lysate; THP1 KO-fortilin , THP1 cells in which the fortilin gene was deleted by CRISPR–Cas9 (KO); THP1 WT-fortilin , THP1 cells expressing WT fortilin (WT); α-UB, anti-ubiquitin Ab; UB(n)-MEF2C, ubiquitinated MEF2C.

Article Snippet: We obtained the recombinant human proteins, MEF2A (catalog no.: TP312830; cMYC-FLAG-tagged), MEF2B (catalog no.: TP327214; cMYC-FLAG-tagged), MEF2C (catalog no.: TP320584; cMYC-FLAG-tagged), MEF2D (catalog no.: TP308748; cMYC-FLAG-tagged), and fortilin (catalog no.: TP301664; cMYC-FLAG-tagged) from OriGene and His 6 - NQO2 (catalog no.: ab93933) from Abcam.

Techniques: Ubiquitin Proteomics, Western Blot, Transfection, Incubation, Expressing, Software, Standard Deviation, Immunoprecipitation, Binding Assay, Mutagenesis, CRISPR

Journal: The Journal of Biological Chemistry

Article Title: Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3

doi: 10.1016/j.jbc.2026.111417

Figure Lengend Snippet: Fortilin promotes the phosphorylation of MEF2C at Ser59 in the N-terminal region. A, phosphorylation status of WT MEF2C in THP1 WT-fortilin and THP1 KO-fortilin cells. THP1 WT-fortilin and THP1 KO-fortilin cells were transiently transfected with the pEZ-MEF2C WT -FLAG plasmid (mock transfection served as a control). MEF2C WT -FLAG was immunoprecipitated from the TCLs using an α-FLAG Ab and subjected to SDS-PAGE. Phosphorylated MEF2C WT protein was visualized by Pro-Q Diamond staining ( top panel ), and total MEF2C WT protein was visualized by SYPRO Ruby staining ( bottom panel ). B, comparison of the phosphorylation status of MEF2C WT and MEF2C M1 in the presence (THP1 WT-fortilin ) and absence (THP1 KO-fortilin ) of fortilin. THP1 WT-fortilin and THP1 KO-fortilin cells were transiently transfected with either pEZ-MEF2C WT -FLAG or pEZ-MEF2C M1 -FLAC plasmids. FLAG-tagged MEF2C WT and MEF2C KO proteins were then immunoprecipitated from the TCLs using an α-FLAG Ab and subjected to SDS-PAGE. Phosphorylated MEF2C proteins were visualized by Pro-Q Diamond staining ( top panel ), and total MEF2C proteins were visualized by SYPRO Ruby staining ( bottom panel ). C – G, evaluation of MEF2C phosphorylation at Ser 59 in the presence and absence of fortilin. Endogenous MEF2C was immunoprecipitated from the TCLs of THP1 WT-fortilin (WT) and THP1 KO-fortilin (KO) cells using anti-MEF2C antibody. Total immunoprecipitated MEF2C and Ser 59 -phosphorylated MEF2C were analyzed using the JESS Western blot system ( C – E ). MEF2C phosphorylation indices were calculated from three independent experiments as the ratio of the area under the curve of phosphorpho-MEF2C signal to that of the total MEF2C signal and expressed in AU. A two-sample t test was used to compare the means of the WT and KO phosphorylation indices ( F and G ). H – J, evaluation of the role of fortilin–MEF2C binding in maintaining MEF2C phosphorylation at Ser 59 . THP1 KO-fortilin cells were transiently transfected with plasmids encoding 3xHA-tagged fortilin WT or fortilin D25A or with nothing. TCLs were analyzed using the JESS Western blot system with α-MEF2C, α-HA, and α-phospho-Ser 59 -MEF2C Abs ( H , I ). The MEF2C phosphorylation index was calculated as the ratio of Ser 59 -phosphorylated MEF2C to total MEF2C ( n = 3; one-way ANOVA with Tukey’s multiple-comparisons test) ( J ). AU, arbitrary unit; α-FLAG, anti-FLAG antibody (Ab); fortilin D25A -HA, pCS-fortilin D25A -3×HA plasmid that expresses the MEF2C-binding–deficient fortilin D25A mutant fused to the three hemagglutinin (HA) epitope tag repeats at its C-terminal end; fortilin WT -HA, pCS-fortilin WT -3×HA plasmid that expresses the WT fortilin fused to the three HA epitope tag repeats at its C-terminal end; α-HA, anti-HA Ab; IB, immunoblot; IP, immunoprecipitation; INPUT, 10% of TCLs used for IP; JESS, an automated capillary-based quantitative Western blot system; KO, THP1 KO-fortilin ; M1, pEZ-MEF2C M1 -FLAG; α-MEF2C, anti-MEF2C Ab; pEZ-MEF2C WT -FLAG, a mammalian expression plasmid containing the construct for FLAG-tagged MEF2C; Pro-Q Diamond, staining for phosphorylated protein; α-Ser 59 , anti-MEF2C-Ser 59 Ab; SYPRO Ruby, staining for total protein; TCL, total cell lysate; WT, THP1 WT-fortilin .

Article Snippet: We obtained the recombinant human proteins, MEF2A (catalog no.: TP312830; cMYC-FLAG-tagged), MEF2B (catalog no.: TP327214; cMYC-FLAG-tagged), MEF2C (catalog no.: TP320584; cMYC-FLAG-tagged), MEF2D (catalog no.: TP308748; cMYC-FLAG-tagged), and fortilin (catalog no.: TP301664; cMYC-FLAG-tagged) from OriGene and His 6 - NQO2 (catalog no.: ab93933) from Abcam.

Techniques: Phospho-proteomics, Transfection, Plasmid Preparation, Control, Immunoprecipitation, SDS Page, Staining, Comparison, Western Blot, Binding Assay, Mutagenesis, Expressing, Construct

Journal: The Journal of Biological Chemistry

Article Title: Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3

doi: 10.1016/j.jbc.2026.111417

Figure Lengend Snippet: Fortilin enhances MEF2C-mediated transcriptional activation of the CTNNA3 promoter. A and B, PLA. Interaction between MEF2C and dsDNA evaluated by PLA. PLA was performed using rabbit α-MEF2C and mouse α-dsDNA Abs in THP1 WT-fortilin (WT, top panels ) and THP1 KO-fortilin (KO, bottom panels ) cells, with nuclei counterstained using DAPI ( blue ). Red puncta indicate that MEF2C and dsDNA are located within 30 nm of each other, signifying a specific interaction. The scale bar represents 10 μm. White squares indicate magnified regions shown below ( A ). The PLA interaction index was calculated as the number of PLA puncta per nucleus within a field of view and is expressed in arbitrary units (AU). Three fields were quantified for each sample, and three independent experiments were performed. Statistical significance was evaluated using a Welch’s two-sample t test ( B ). C, structure of the human CTNNA3 gene ( top panel ) and pGL-P CTNNA3 -Luc reporter vector ( bottom panels ). A high-probability MEF2C binding site was identified within the 3266-nucleotide CTNNA3 promoter region using the JASPAR platform. This 3266-nucleotide CTNNA3 promoter region that contains a top-scoring, predicted MEF2C binding motif (ATAAAAATACA) located from −976 to −966 relative to the transcription start site (TSS) was cloned upstream of the firefly luciferase reporter gene in the pGL vector to generate pGL-P CTNNA3-Luc vector (total size = 8230 base pairs). D, dual luciferase reporter assay to assess the impact of fortilin on CTNNA3 promoter activation. 293T cells were sequentially transfected with siRNA targeting fortilin (siRNA fortilin ) or control siRNA (siRNA control ), followed by cotransfection with pRL-null vector ( Renilla luciferase, normalization control) and either pGL-P Control-Luc or pGL-P CTNNA3 -Luc reporter plasmids. Luciferase activity was measured 24 h post-transfection, and the RAI was calculated as the ratio of firefly to Renilla luciferase activity. Data are expressed as means ± standard deviation ( n = 3 biological replicates) and were analyzed using two-way ANOVA followed by Tukey–Kramer multiple comparisons. E and F, dual luciferase reporter assay to determine whether MEF2C is required for fortilin-mediated activation of the CTNNA3 promoter. 293T cells were transfected with one of the following siRNA combinations: (i) siRNA MEF2C + siRNA control , (ii) siRNA MEF2C + siRNA fortilin , (iii) siRNA control , or (iv) siRNA fortilin . Luciferase activity was measured 24 h post-transfection, and the RAI was calculated. Data are presented as means ± standard deviation ( n = 4) and were analyzed using two-way ANOVA and Tukey’s multiple comparisons ( E ). Subsequently, cell lysates were subjected to Western blotting using α-MEF2C and α-fortilin Abs to confirm siRNA-mediated knockdown of target genes ( F ). G and H, TATA-binding protein (TBP) and RNA polymerase II (Pol II) chromatin immunoprecipitation (ChIP) of CTNNA3. ChIP assays were performed in THP1 WT-fortilin and THP1 KO-fortilin cells by crosslinking chromatin with formaldehyde, followed by immunoprecipitation of chromatin from the TCLs using an anti-TBP ( G ) or anti-Pol II ( H ) antibody coupled to Protein A/G beads. Normal IgG was used as a negative control. DNA from the immunoprecipitated chromatin was purified and analyzed by quantitative PCR (qPCR) using primers flanking the transcription start sites (TSSs) of CTNNA3 , CD68 (positive control), and V WF (negative control). TBP ( G ) and Pol II ( H ) occupancy indices for CTNNA3, CD68, and vWF were expressed as fold enrichment values (AU) relative to IgG ( n = 4; Student's t test for TBP ( G ) and Welch’s t tests for Pol II ( H ). I and J, CTNNA3 expression in THP1 KO-fortilin cells overexpressing WT (fortilin WT ) and an MEF2C-binding–deficient (fortilin D25A ) fortilin. THP1 KO-fortilin cells were transiently transfected with plasmids encoding HA-tagged fortilin WT or fortilin D25A . Untransfected THP1 KO-fortilin cells were used as controls. TCLs were analyzed using the JESS automated Western blot system with anti-HA and anti-CTNNA3 antibodies ( I ). The CTNNA3 expression index was calculated by normalizing the area under the CTNNA3 peak to the total protein signal and expressed as arbitrary units (AU) ( n = 3; one-way ANOVA with Tukey’s multiple comparisons) ( J ). AU, arbitrary unit; α-CTNNA3, anti-CTNNA3 antibody; ChIP–qPCR, chromatin immunoprecipitation–quantitative PCR; DAPI, 4′,6-diamidino-2-phenylindole; α-dsDNA, anti–double-stranded DNA antibody (Ab); α-fortilin, anti-fortilin Ab; Fortilin WT, THP1 WT-fortilin , THP1 cells expressing WT fortilin; Fortilin KO, THP1 KO-fortilin , THP1 cells in which the fortilin genes have been deleted by the CRISPR–Cas9 technology; α-HA, anti-HA-epitope-tag antibody; IB, immunoblot; α-MEF2C, anti-MEF2C Ab; pGL-P Control , pGL-luciferase vector with no promoter; pGL-P CTNNA3 -Luc, pGL luciferase vector in which the CTNNA3 promoter is fused to the firefly luciferase construct; PLA, proximity ligation assay; Plasmid-D25A, pCS-fortilin D25A -3×HA plasmid that expresses the MEF2C-binding–deficient fortilin D25A mutant fused to the three HA epitope tag repeats at its C-terminal end; Plasmid-WT, pCS-fortilin WT -3×HA plasmid that expresses the WT fortilin fused to the three hemagglutinin (HA) epitope tag repeats at its C-terminal end; RAI, relative activity index; TCE, 2,2,2-trichloroethanol; TCL, total cell lysate.

Article Snippet: We obtained the recombinant human proteins, MEF2A (catalog no.: TP312830; cMYC-FLAG-tagged), MEF2B (catalog no.: TP327214; cMYC-FLAG-tagged), MEF2C (catalog no.: TP320584; cMYC-FLAG-tagged), MEF2D (catalog no.: TP308748; cMYC-FLAG-tagged), and fortilin (catalog no.: TP301664; cMYC-FLAG-tagged) from OriGene and His 6 - NQO2 (catalog no.: ab93933) from Abcam.

Techniques: Activation Assay, Plasmid Preparation, Binding Assay, Clone Assay, Luciferase, Reporter Assay, Transfection, Control, Cotransfection, Activity Assay, Standard Deviation, Western Blot, Knockdown, Chromatin Immunoprecipitation, Immunoprecipitation, Negative Control, Purification, Real-time Polymerase Chain Reaction, Positive Control, Expressing, ChIP-qPCR, CRISPR, Construct, Proximity Ligation Assay, Mutagenesis

Journal: The Journal of Biological Chemistry

Article Title: Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3

doi: 10.1016/j.jbc.2026.111417

Figure Lengend Snippet: Fortilin binds the transcription factor MEF2C, protects it against proteasomal degradation, enhances its phosphorylation, and transcriptionally activates the CTNNA3 promoter. Under normal conditions (Fortilin [+], left panel ), fortilin binds MEF2C and protects it from proteasomal degradation ① . In addition, fortilin facilitates the phosphorylation of MEF2C ② , thereby enhancing its DNA binding capacity and promoting transcriptional activation of the CTNNA3 gene ③ . In contrast, under fortilin-deficient conditions (Fortilin [–], right panel ), MEF2C undergoes increased proteasomal degradation and becomes less phosphorylated at Ser 59 , which impairs its ability to bind the CTNNA3 promoter and transcriptionally activate the gene, ultimately leading to cellular dysfunction. FT, fortilin; P, phosphorylation.

Article Snippet: We obtained the recombinant human proteins, MEF2A (catalog no.: TP312830; cMYC-FLAG-tagged), MEF2B (catalog no.: TP327214; cMYC-FLAG-tagged), MEF2C (catalog no.: TP320584; cMYC-FLAG-tagged), MEF2D (catalog no.: TP308748; cMYC-FLAG-tagged), and fortilin (catalog no.: TP301664; cMYC-FLAG-tagged) from OriGene and His 6 - NQO2 (catalog no.: ab93933) from Abcam.

Techniques: Phospho-proteomics, Binding Assay, Activation Assay

Journal: Scientific Reports

Article Title: Myocyte-specific enhancer factor 2c triggers transdifferentiation of adipose tissue-derived stromal cells into spontaneously beating cardiomyocyte-like cells

doi: 10.1038/s41598-020-80848-3

Figure Lengend Snippet: Gata4, Mef2c, and Tbx5 expression in the beating and non-beating groups. ( a ) Left three panels, gene expression levels in the beating and non-beating group. Right panel, gene expression levels in the beating and non-beating group relative to that of β-actin. ( b ) Representative immunofluorescence images of a cluster of round cells expressing Gata4 and Mef2c on day 14. ( c ) Phase-contrast and immunofluorescence images of beating cells expressing cardiac troponin T (cTnT) and Mef2c on day 28. The arrowhead indicates a beating cell. Scale bar, 100 µm. DAPI, 4′,6-diamidino-2-phenylindole, ** p < 0.01; **** p < 0.0001 by t -test or ANOVA and Tukey’s post hoc test. ( d ) The frequency of round cells expressing Gata4 and Mef2c (10 round cells were examined per experiment, n = 13). ( e ) The frequency of beating cells expressing Mef2c and cTnT (15 beating cells were analysed per experiment, n = 4).

Article Snippet: For silencing of mouse Mef2c, LentiORF lentiviral particles of mouse Mef2c-specific short hairpin RNA (TL511428V, Origene) or scrambled control were used.

Techniques: Expressing, Gene Expression, Immunofluorescence

Journal: Scientific Reports

Article Title: Myocyte-specific enhancer factor 2c triggers transdifferentiation of adipose tissue-derived stromal cells into spontaneously beating cardiomyocyte-like cells

doi: 10.1038/s41598-020-80848-3

Figure Lengend Snippet: Overexpression of SVF with Mef2c augments the number of round cells and their transdifferentiation into CMs. ( a – d ) Phase-contrast images of SVF on day 28 after transfection on day 5 ( a , control; b , Gata4; c , Mef2c; d , Tbx5). Arrowheads indicate round cells; lv, lentivirus vector. ( e ) mRNA level of Mef2c, determined by qRT-PCR, on day 28 in SVFs transfected with the control vector and Mef2c-lv (left), or scrambled shRNA and shMef2c-lv (right), on day 5, respectively. shRNA, short hairpin RNA; shMef2c, shRNA targeting Mef2c. ( f ) Number of round cells on day 14 after introducing SVF with none (none) or the control, Gata4, Mef2c, shMef2c, or Tbx5 lentivirus vector. ( g ) mRNA level of cardiac troponin T by qRT-PCR on day 28 in SVF transfected with the control, Gata4, Mef2c, shMef2c, or Tbx5. ( h ) Relationship between the mRNA levels of Mef2c and cardiac troponin T in the SVF transduced with Mef2c. R, Pearson’s product-moment correlation coefficient. The linear interpolation formula is displayed. Scale bar = 100 µm. * p < 0.05; ** p < 0.01; **** p < 0.0001 by ANOVA and Tukey’s post hoc test.

Article Snippet: For silencing of mouse Mef2c, LentiORF lentiviral particles of mouse Mef2c-specific short hairpin RNA (TL511428V, Origene) or scrambled control were used.

Techniques: Over Expression, Transfection, Control, Plasmid Preparation, Quantitative RT-PCR, shRNA, Transduction

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 1. ETP/immature subtype pediatric and young adult patients with T-ALL highly express MEF2C and other stem cell factors HHEX, LMO2, BCL2, and LYL1. (A) Cluster analysis of 264 pediatric and young adult patients with T-ALL from the St. Jude study by Liu et al. (6) based on 371 available genes out of the 416-gene set (435 probe sets) as originally defined in the unsupervised cluster analysis of 117 pediatric patients with T-ALL by Homminga et al. (5). Specific clusters have been indicated as TLX1/NKX2.1 (formerly denoted as proliferative subtype), HOX, TLX3 (both formerly included in the TLX cluster), TALLMO, and ETP/immature. Specific oncogenic rearrangements are indicated for driving oncogenes, and patient characteristics include immunopheno- typic ETP, near ETP, and non-ETP patients. The absence of biallelic TRG deletions (ABD) are indicated as reported before (6). (B and C) Distribution of ETP, near ETP, and non-ETP cases or ABD and non-ABD patients with T-ALL over the ETP/immature cluster versus other T-ALL clusters.

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques:

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 2. MEF2C antagonizes Notch signaling in early progenitor T cells and induces B cell gene expression. (A) TCRγδ/CD3ε surface expression on LOUCY cells that were cultured in media or cocultured for 3 days on OP9-DL1 stromal cells, in the absence or presence of 10 μM of γ-secretase inhibitor DAPT visualized by flow cytometry (n = 3). (B) Transduced LOUCY cells containing a dox-inducible MEF2C-BFP overexpression construct (middle panels) or an IPTG-inducible MEF2C shRNA knockdown construct (bottom panels) were generated and compared with parental LOUCY cells (top panels). Blue fluorescence (BFP, blue-filled histograms), intracellular MEF2C levels (green-filled histograms), and surface CD3ε levels (red-filled histograms) were analyzed using flow cytometry in the absence (open histograms) or presence of dox or IPTG, respectively (filled histograms), as indicated. “Endog. MEF2C” refers to endogenous MEF2C expression levels in the MEF2C shRNA knockdown line. CD3ε expression after coculture on OP9 control or OP9-DL1 stromal cells (right columns). (C) Significantly enriched up- (red) or downregulated (blue) GO terms in MEF2C-induced LOUCY cells for 24 hours compared with noninduced LOUCY cells. (D) Heatmaps of significantly up- or downregulated probe sets (log2 fold change >0.6, P < 0.05, FDR < 0.1) in triplicate gene expression analysis (Affymetrix GeneChip Human Genome U133 Plus 2.0) per condition for LOUCY_MEF2C-BFP cells with/without MEF2C induction for 24 hours (± dox). Downregulated or upregulated probe sets following MEF2C-induction are shown in blue or red, respectively. Three of the 4 MEF2C probe sets, designated with asterisks, lie outside the cloned MEF2C cDNA sequence and thus represent endogenous MEF2C levels, whereas the other MEF2C probe set (indicated by the arrow) also covers the cloned cDNA construct.

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques: Gene Expression, Expressing, Cell Culture, Flow Cytometry, Over Expression, Construct, shRNA, Knockdown, Generated, Fluorescence, Control, Clone Assay, Sequencing

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 3. MEF2C binds to promoters and enhancers, which is reduced by Notch signaling. (A) Color-coded centered heatmaps indicating ChIP-Seq peak binding intensities (number of reads in a –1.0 kb to +1.0 kb region relative to the summit of the peak) for MEF2C, Bromodomain 4 (BRD4), and histone H3 with epigenetic trimethylation (H3K4me3) or acetylation marks (H3K27ac) for LOUCY parental cells (blue) or LOUCY parental cells cultured on OP9-DL1 stromal cells for 24 hours (green). Centered heatmaps for 5 kb regions upstream of transcription start site (uTSS), GeneHancer-defined enhancers (Enh), 5 kb regions upstream of long noncoding areas (defined by deepbase and lncipedia [uLnc]), or other regions (Supplemental Figure 3). (B) The number of upregulated genes (from collapsed probe sets; red circle) and downregulated genes (blue circle) with a log2 fold change > 0.6 (with P < 0.05 and q < 0.1) 24 hours after induction of MEF2C expression are displayed (see also Figure 2, C and D). The smaller black circles indicate the number of genes having MEF2C binding sites within the gene body or within 10 kb flanking regions. (C) Motifs as identified by MEME-ChIP found within 50 bp upstream or downstream regions relative to the MEF2C ChIP-Seq peak summits (101 bp window) are indicated including their expectancy values (E value), the number of sites identified, and their relative locations in these windows.

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques: ChIP-sequencing, Binding Assay, Cell Culture, Expressing

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 4. MEF2C induces BCL2 and provides a survival advantage under limiting serum levels. (A) LOUCY_MEF2C-BFP cells were cultured in triplicate without (dashed lines) or following induction of MEF2C (+dox, solid lines) in media containing 0%, 1%, or 10% fetal calf serum (FCS; mean values ± SD are shown). (B) Per- centage of cells expressing the MEF2C-BFP construct in the derivative LOUCY_MEF2C-BFP bulk line. Triplicate experiments grown for 22 days in the presence of 1% (left) or 10% (right) FCS. Each column displays the fraction of MEF2C-BFP expressing cells in blue. (C) LOUCY_MEF2C-BFP cells were grown in medium containing 1% FCS without (–dox, gray line) or with MEF2C-BFP induction (+dox, blue line). Dox was washed out at day 17 (dashed blue line), and cells were further cultured in 1% FCS media without dox. Mean values ± SD from an experiment in triplicate are shown; shown are representative examples of 3 independent experiments performed. (D) Western blot for MEF2C and BCL2 in LOUCY_MEF2C-BFP cells that were grown in 1% or 10% FCS media for 3 days without (–dox) or with MEF2C induction (+dox). Relative band intensities for BCL2 normalized to β-actin are indicated, with the –dox condition ratio set at 1. (E) Western blot of phospho-STAT5 (Tyr694), total STAT5, and BCL2 in LOUCY_MEF2C-BFP cells that were grown in 10% FCS media without (–dox) or with MEF2C induction (+dox) for 24 hours and subsequently incubated without and with 100 ng/mL IL-7 for 15 minutes (top) or 2 days (bottom). Ruxolitinib (2 μM) was added for 1 hour before IL-7 addition and remained present throughout the experiment. β-Actin was used as a loading control. Relative band intensity ratios for phospho-STAT5 (normalized to total STAT5 level) and for BCL2 (normalized to β-actin) are shown as explained in D.

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques: Cell Culture, Expressing, Construct, Western Blot, Incubation, Control

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 5. MEF2C blocks T cell development. (A) MEF2C-eGFP transgenic mice: loxP-flanked stop cassette followed by MEF2C cDNA, IRES, and eGFP following exon 1 of the Rosa26 locus (top). Cre recombinase activity removes the stop cassette and activates expression of MEF2C and eGFP from the Rosa26 promoter (bottom). SA, splice acceptor site; arrows, genotyping primers. (B) Genotype of spleens of mice with WT or MEF2C-eGFP transgene (tg) alleles, in the absence or the presence of Lck-Cre. (C) Western blot of endogenous or induced MEF2C and α-tubulin protein levels in total thymocytes from mice of different genotypes. (D) Flow cytometry histograms of eGFP expression in lymph node or thymus cells from duplicate MEF2C-eGFP hetero- or homozygous mice with or without Lck-Cre as indicated by the gray, light green, and dark green histograms. (E) Absolute cell numbers (mean ± SD) for cells from MEF2C-eGFP control (no Cre, open circles) and MEF2C-eGFP/Lck-Cre mice (blue filled circles) at 10–16 and 20–34 weeks of age. Populations are CD4/CD8 DN, DP, CD4 SP, and CD8 SP. DN are also gated on lineage– (CD3, B220, CD11b, Ly6G/C, Ter-119) cells to further divide the immature thymocyte populations into DN1-DN4. DN1, CD44+CD25–; DN2, CD44+CD25+; DN3, CD44–CD25+; DN4, CD44–CD25–. (F) Total CD45+ cell numbers (mean ± SD) as in E in the thymus (left panel) or inguinal lymph nodes (right panel). (G) Total CD19+ cell numbers (mean ± SD) as in E in the BM (left panel) or thymus (right panel). *P < 0.05, **P < 0.01 by Mann-Whitney U test.

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques: Transgenic Assay, Activity Assay, Expressing, Western Blot, Flow Cytometry, Control, MANN-WHITNEY

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 6. MEF2C blocks T cell lineage differentiation in murine and human cocultures. (A) Mouse differentiation assay: lineage-depleted (CD3, B220, CD11b, Ly6G/C, 7-4, Ter-119) BM cells from MEF2C-eGFPtg/tg mice were exposed to Tat-Cre before a coculture experiment (day 0) on OP9-DL1 or OP9 stromal cells to monitor T and B cell differentiation, respectively. (B) Human differentiation assay: human CD34+ cells from healthy umbilical cord blood donors transduced with BFP control (left) or MEF2C-t2a-BFP (right) lentiviruses and cocultured on OP9-DL1 stromal cells for 2 or 5 days. (C) Transduction as in B, but at day 12 after splitting the coculture. CD45+ cell numbers of a representative example of 3 independent coculture experiments are displayed. For transduced cells, the BFP+ percentage is indicated.

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques: Differentiation Assay, Cell Differentiation, Transduction, Control

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 7. MEF2C induces tumors in mice. (A) Flow cytometry analysis of CD3+ and/or CD19+ cell fractions of CD45+ thymus or BM cells from MEF2C-eGFP/Lck-Cre mouse #3 (with tumor) and mouse #5 (no tumor). (B) Summary of CD3+ and/or CD19+ cell fractions of GFP+CD45+ cells from 3 MEF2C-eGFP/Lck-Cre mice with tumors (mice #1–#3) and 3 mice without evidence of tumor growth (mice #4–#6). Percentages of different cell populations are indi- cated: CD3+CD19+ (red), CD3+ (green), CD19+ (blue), and CD3–CD19– (gray) cells. (C) Summary of CD3+ and/or CD19+ cell fractions of GFP+CD45+ cells as in B in NSG mice that were transplanted with tumors from indicated tissues of MEF2C-eGFP mice #1–#3 (arrows). Nine of 14 transplanted NSG mice are shown. (D) Survival curves of 14 NSG mice transplanted with MEF2C-eGFP/Lck-Cre tumors (red line) and 2 control NSG mice transplanted with splenocytes from 2-year-old MEF2C-eGFP/no-Cre control mice (black line).

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques: Flow Cytometry, Control

Journal: JCI insight

Article Title: MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.

doi: 10.1172/jci.insight.150363

Figure Lengend Snippet: Figure 8. SIK inhibitors block MEF2C function. (A) Effects of the compounds from the Selleck Epigenetic Compound Library and various additional inhibi- tors (1 μM) were screened for their potential to induce a CD3ε+ phenotype in LOUCY cells on DLL4-coated plates. As controls, media, non-DLL4–stimulated cells or MEF2C-overexpressing (LOUCY_MEF2C-BFP) cells (+dox) have been indicated in blue. Normalized CD3ε fluorescence intensities have been plotted for duplicate experiments. (B) SIK kinase inhibitors YKL-06-062 and HG-9-91-01; dasatinib, which has SIK off-target activity (12 nM, 48 nM, and 180 nM for SIK1, SIK2, or SIK3, respectively) (MedChemExpress or Proteomicsdb.org), and imatinib were tested to induce a CD3ε+ phenotype in LOUCY_MEF2C- BFP cells when cultured on DLL4-coated plates in the absence of dox (except when indicated). (C) Western blot of MEF2C, P-MEF2C (Ser222), and BCL2 in noninduced (no dox) or MEF2C-induced (+dox) LOUCY_MEF2C-BFP cells that were incubated in the presence of increasing concentrations of inhibitors HG-9-91-01 for 4 days. Band intensity ratios for various proteins relatively to β-actin control levels is indicated, with the –dox condition set at the value = 1. (D) Cell viability of noninduced (no dox) or MEF2C-induced (+dox) LOUCY_MEF2C-BFP after a 4-day exposure to a serial dilution of prednisolone combined with a serial dilution of HG-9-91-01 at the concentrations indicated. ZIP synergy scores are calculated from an n = 3 per condition. ZIP scores < –10 are indicated with a dash-dot line and a blue color. ZIP scores > 10 are indicated by a dashed line.

Article Snippet: Western blot antibodies Western blot antibodies were obtained from Cell Signaling Technology unless specified otherwise: MEF2C (catalog 5030), Cleaved NOTCH1 Val1744 (catalog 4147), MAML1 (catalog 11959), STAT5 (catalog 94205), phospho-STAT5 Tyr694 (catalog 9351), HA-tag (catalog 3724), DDK-tag (catalog 2368), HDAC4 (catalog 15164), phospho–HDAC4 Ser246/HDAC5 Ser259/HDAC7 Ser155 (catalog 3443), BCL2 (Santa Cruz Biotechnology Inc., sc-130308), LAMIN B (Santa Cruz Biotechnology Inc., sc-6216), β-actin (Abcam, ab6276), phospho-Ser222 MEF2C (PhosphoSolutions, p1208-222), and SIK3 (Sigma-Aldrich, HPA048161).

Techniques: Blocking Assay, Drug discovery, Fluorescence, Activity Assay, Cell Culture, Western Blot, Incubation, Control, Serial Dilution